Madrigal logo.jpg
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
May 17, 2022 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic...
Madrigal logo.jpg
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
May 09, 2022 06:30 ET | Madrigal Pharmaceuticals, Inc.
MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™Data from the Phase 3 MAESTRO-NAFLD-1 study continue to...
TIP_link_300x300.jpg
Photoacoustic Tomography Market Worth $209.56 Million, Globally, by 2028 at 19.2% CAGR - Exclusive Report by The Insight Partners
April 11, 2022 01:30 ET | The Insight Partners
New York, April 11, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Photoacoustic Tomography Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Kizoo_Logo for GNW.jpg
Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round
April 07, 2022 07:00 ET | KIZOO Technology Capital GmbH
GREENVILLE, S.C., April 07, 2022 (GLOBE NEWSWIRE) -- Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and...
Flow Therapy Adds World-Renowned Cardiologist Timothy D. Henry to Board of Directors
April 06, 2022 09:00 ET | Flow Therapy
FORT WORTH, Texas, April 06, 2022 (GLOBE NEWSWIRE) -- World-renowned cardiologist Timothy D. Henry, MD, FACC, MSCAI, has joined Flow Therapy's Board of Directors. Dr. Henry is the Lindner Family...
researchdrivelogo.jpg
Global Digital therapeutics Market to Perceive Noteworthy Growth Due to Growing Cases of Chronic Disorders Worldwide [175-Pages] | Divulge by Research Dive
March 21, 2022 09:03 ET | Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- A new report on the global digital therapeutics market has been added by Research Dive to its repository. As per the report, the market is expected...
Global Cardiac Resynchronization Therapy Markets Analysis & Forecasts Report 2017-2021 & 2022-2030 Featuring Abbott, Boston Scientific, Medtronic, Biotronik Se & Co, & Microport Scientific
March 04, 2022 04:48 ET | Research and Markets
Dublin, March 04, 2022 (GLOBE NEWSWIRE) -- The "Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report by Product (CRT-defibrillator, CRT-pacemaker), by End User...
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
February 28, 2022 06:28 ET | Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
22157.jpg
Global Cardiology IT Workflow Solutions Market 2022-2026: A $1.3 Billion Opportunity Assessment
February 23, 2022 04:53 ET | Research and Markets
Dublin, Feb. 23, 2022 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Wide...
Madrigal logo.jpg
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
January 31, 2022 07:00 ET | Madrigal Pharmaceuticals, Inc.
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80...